Search Result(s)

MSF statement supporting the extension of TRIPS (affordable drugs for the poorest countries) exemption for least-developed countries

Backgound: Least-developed country (LDC) members of the World Trade Organization (WTO) have requested an extension that would enable them to remain exempt from implementing some intellectual property rules expiring next year, including for medicines. MSF urges all WTO members to support this +request. MSF works in more than 20 LDCs, facing multiple challenges including disease outbreaks, conflicts and natural disasters. The COVID-19 pandemic has heavily hit some LDCs already facing long-term challenges of fragile health care systems and lack of access to affordable medical tools.

MSF briefing and position paper regarding WHA73 and COVID-19

MSF recommends the following actions to ensure access and equitable allocation of COVID-19 medical tools: * Adopt binding and enforceable measures * Encourage Member States to explore and use fully the existing policy and legal measures, including flexibilities under the TRIPS Agreement and the Doha Declaration on TRIPS and Public Health * Ensure full transparency of all R&D funding agreements with explicit and binding obligations Briefing: https://msfaccess.org/sites/default/files/2020-05/WHA73-Briefing-12May2020.pdf Position paper: https://msfaccess.org/msf-access-campaign-position-paper-sharing-technologies-covid-19-ensure-equitable-access-all